AU2020378648A1 - Therapeutic derivatives of Interleukin-22 - Google Patents

Therapeutic derivatives of Interleukin-22 Download PDF

Info

Publication number
AU2020378648A1
AU2020378648A1 AU2020378648A AU2020378648A AU2020378648A1 AU 2020378648 A1 AU2020378648 A1 AU 2020378648A1 AU 2020378648 A AU2020378648 A AU 2020378648A AU 2020378648 A AU2020378648 A AU 2020378648A AU 2020378648 A1 AU2020378648 A1 AU 2020378648A1
Authority
AU
Australia
Prior art keywords
derivative
hil
disease
derivatives
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020378648A
Other languages
English (en)
Inventor
Thomas Hoeg-Jensen
Rasmus JØRGENSEN
Sebastian Beck JØRGENSEN
Michael Paolo Bastner SANDRINI
Kristian SASS-ØRUM
Henning THØGERSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytoki Pharma ApS
Original Assignee
Cytoki Pharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoki Pharma ApS filed Critical Cytoki Pharma ApS
Publication of AU2020378648A1 publication Critical patent/AU2020378648A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
AU2020378648A 2019-11-07 2020-11-09 Therapeutic derivatives of Interleukin-22 Abandoned AU2020378648A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207766.7 2019-11-07
EP19207766.7A EP3819307A1 (en) 2019-11-07 2019-11-07 Therapeutic derivatives of interleukin-22
PCT/EP2020/081523 WO2021089875A1 (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22

Publications (1)

Publication Number Publication Date
AU2020378648A1 true AU2020378648A1 (en) 2022-06-23

Family

ID=68502950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020378648A Abandoned AU2020378648A1 (en) 2019-11-07 2020-11-09 Therapeutic derivatives of Interleukin-22

Country Status (19)

Country Link
US (5) US11806403B2 (enExample)
EP (2) EP3819307A1 (enExample)
JP (2) JP2023502005A (enExample)
KR (1) KR20220097921A (enExample)
CN (2) CN118359699A (enExample)
AU (1) AU2020378648A1 (enExample)
BR (1) BR112022008497A2 (enExample)
CA (1) CA3160338A1 (enExample)
CL (1) CL2022001185A1 (enExample)
CO (1) CO2022005889A2 (enExample)
CR (1) CR20220249A (enExample)
GE (2) GEAP202415970A (enExample)
IL (1) IL292657A (enExample)
MX (1) MX2022005547A (enExample)
MY (1) MY209488A (enExample)
PE (1) PE20221279A1 (enExample)
PH (1) PH12022551107A1 (enExample)
SA (1) SA522432487B1 (enExample)
WO (1) WO2021089875A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
CN115955976A (zh) * 2020-04-17 2023-04-11 小利兰·斯坦福大学董事会 工程化白介素-22多肽及其用途
EP4389138A1 (en) 2022-12-22 2024-06-26 Cytoki Pharma ApS Dosage regimen for interleukin-22 derivatives
JP2025542282A (ja) 2022-12-22 2025-12-25 サイトカイ・ファーマ・アーペーエス インターロイキン－２２誘導体の投薬レジメン
CN119708194A (zh) * 2023-09-28 2025-03-28 南京诺艾新生物技术有限公司 Il-22突变体及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR106F (enExample) 1964-12-21
CA2718634A1 (en) 2008-03-21 2009-09-24 Wyeth Llc Antibodies against interleukin-10-like cytokines and uses therefor
TW201143790A (en) * 2010-05-13 2011-12-16 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
JP2013533227A (ja) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
ES2800983T3 (es) * 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
CA2878825A1 (en) 2012-07-10 2014-01-16 The Uab Research Foundation Compositions and methods for modulation of il-20 family cytokine activity
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
WO2015038938A1 (en) * 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10695406B2 (en) 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
CN106146668A (zh) 2015-04-01 2016-11-23 中国人民解放军第二军医大学 长效白细胞介素22的制备方法及其用途
HK1257747A1 (zh) * 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
IL321812A (en) * 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CN111655717A (zh) 2018-01-26 2020-09-11 豪夫迈·罗氏有限公司 IL-22 Fc融合蛋白及使用方法
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
CN115955976A (zh) 2020-04-17 2023-04-11 小利兰·斯坦福大学董事会 工程化白介素-22多肽及其用途
US20240279297A1 (en) 2021-05-11 2024-08-22 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
EP4089107A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22

Also Published As

Publication number Publication date
CN118359699A (zh) 2024-07-19
KR20220097921A (ko) 2022-07-08
US12226487B2 (en) 2025-02-18
PE20221279A1 (es) 2022-09-05
CN114761422B (zh) 2026-01-02
US20260014257A1 (en) 2026-01-15
US20240108731A1 (en) 2024-04-04
CN114761422A (zh) 2022-07-15
JP2023083380A (ja) 2023-06-15
CL2022001185A1 (es) 2023-02-03
MY209488A (en) 2025-07-12
BR112022008497A2 (pt) 2022-07-26
EP4055035A1 (en) 2022-09-14
US20230381320A1 (en) 2023-11-30
MX2022005547A (es) 2022-07-04
US11806403B2 (en) 2023-11-07
JP7479539B2 (ja) 2024-05-08
EP3819307A1 (en) 2021-05-12
US12447211B2 (en) 2025-10-21
PH12022551107A1 (en) 2023-11-20
GEAP202415970A (en) 2024-12-25
US20220347304A1 (en) 2022-11-03
SA522432487B1 (ar) 2024-10-01
CR20220249A (es) 2022-08-19
JP2023502005A (ja) 2023-01-20
WO2021089875A1 (en) 2021-05-14
IL292657A (en) 2022-07-01
GEP20257757B (en) 2025-04-10
CO2022005889A2 (es) 2022-07-29
US20240252649A1 (en) 2024-08-01
CA3160338A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
US11806403B2 (en) Therapeutic derivatives of interleukin-22
US11111285B2 (en) Glucagon-GLP-1-GIP triple agonist compounds
US11008375B2 (en) GIP-GLP-1 dual agonist compounds and methods
US20240279297A1 (en) Therapeutic derivatives of interleukin-22
KR20210013300A (ko) 장기 작용성 성장 호르몬 및 이의 제조 방법
CN117597357A (zh) 白细胞介素-22的治疗性衍生物
CN117616035A (zh) 白介素-22的治疗性衍生物
EA049770B1 (ru) Терапевтические производные интерлейкина-22
HK40108760A (en) Therapeutic derivatives of interleukin-22
WO2024133936A2 (en) Dosage regimen for interleukin-22 derivatives
CA2643736A1 (en) Methods and compositions to treat mucositis

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application